Literature DB >> 24022094

Peginterferon plus Chinese herbal therapy is associated with a higher virological response than only peginterferon therapy in chronic hepatitis C.

D Cheng, E Liu, Y Li, R Liu, L Bai, Y Chen, Y Wang, Y Chu, M Wu, G Cheng, S Zhao.   

Abstract

Traditional Chinese herbal therapies are widely used for the treatment of chronic hepatitis C (CHC) in China and several Asian countries. The aim of this study was to perform a meta-analysis of randomized controlled trials (RCTs) comparing peginterferon therapy with peginterferon plus Chinese herbal therapy for the treatment of CHC. The Cochrane Central Register of Controlled Trials, Medline, Science Citation Index, EMBASE, China National Knowledge Infrastructure, Wanfang Database, and China Biomedical Database were searched to identify RCTs that evaluated the virological response of CHC patients to peginterferon therapy and peginterferon plus Chinese herbal therapy. We statistically combined data using a fixed-effects meta-analysis according to the intention-to-treat principle. The literature search yielded 905 studies and nine RCTs composed of 858 patients matched the selection criteria. Overall, sustained virological response (SVR) was significantly higher in patients treated with peginterferon plus Chinese herbs than in patients treated with peginterferon alone (81 % vs. 64 %, respectively; odds ratio, 2.60; 95 % confidence interval: 1.32–5.14; p < 0.05). A combined therapy of peginterferon plus Chinese herbs was also superior to peginterferon therapy in achieving an early viral response (EVR, 80 % vs. 70 %, respectively), a viral response at week 24 of treatment (82 % vs. 73 %, respectively), and end-of-treatment viral response (ETVR, 73 % vs. 62 %, respectively). The combined therapy resulted in fewer relapses, fewer adverse events, and more rapid alanine transaminase normalization; however, both treatments yielded a similar rapid viral response (RVR, 53 % vs. 57 %, respectively). The current evidence suggests that combined therapy of peginterferon plus Chinese herbs yields a higher viral response and results in fewer relapses and fewer adverse events than peginterferon therapy alone.

Entities:  

Mesh:

Substances:

Year:  2014        PMID: 24022094     DOI: 10.1007/s10096-013-1973-y

Source DB:  PubMed          Journal:  Eur J Clin Microbiol Infect Dis        ISSN: 0934-9723            Impact factor:   3.267


  17 in total

Review 1.  Hepatitis C virus infection.

Authors:  G M Lauer; B D Walker
Journal:  N Engl J Med       Date:  2001-07-05       Impact factor: 91.245

2.  [Pegasys: FDA approved Pegasys (peginterferon alfa-2a) for the treatment of hepatitis C].

Authors:  Mauricio Iafolla
Journal:  Sidahora       Date:  2002

Review 3.  Hepatitis C: the clinical spectrum of disease.

Authors:  J H Hoofnagle
Journal:  Hepatology       Date:  1997-09       Impact factor: 17.425

Review 4.  Pathogenesis, natural history, treatment, and prevention of hepatitis C.

Authors:  T J Liang; B Rehermann; L B Seeff; J H Hoofnagle
Journal:  Ann Intern Med       Date:  2000-02-15       Impact factor: 25.391

5.  Interferon plus Chinese herbs are associated with higher sustained virological response than interferon alone in chronic Hepatitis C: a meta-analysis of randomised trials.

Authors:  Sihai Zhao; Enqi Liu; Kena Wei; Shemin Lu; Yonglie Chu; Yafeng Li; Yanli Wang; Bingqiao Huang; Yulong Chen; Penghui Yang
Journal:  Antiviral Res       Date:  2010-12-15       Impact factor: 5.970

6.  Rapid virological response is the most important predictor of sustained virological response across genotypes in patients with chronic hepatitis C virus infection.

Authors:  Michael W Fried; Stephanos J Hadziyannis; Mitchell L Shiffman; Diethelm Messinger; Stefan Zeuzem
Journal:  J Hepatol       Date:  2010-11-23       Impact factor: 25.083

7.  Peginterferon alfa-2b plus ribavirin compared with interferon alfa-2b plus ribavirin for initial treatment of chronic hepatitis C: a randomised trial.

Authors:  M P Manns; J G McHutchison; S C Gordon; V K Rustgi; M Shiffman; R Reindollar; Z D Goodman; K Koury; M Ling; J K Albrecht
Journal:  Lancet       Date:  2001-09-22       Impact factor: 79.321

8.  Treatment with peginterferon versus interferon in Chinese patients with chronic hepatitis C.

Authors:  S Zhao; E Liu; K Wei; Y Wang; Y Li; B Huang; Y Chen; P Yang
Journal:  Eur J Clin Microbiol Infect Dis       Date:  2010-09-09       Impact factor: 3.267

Review 9.  Treatment with peginterferon plus ribavirin vs. interferon plus ribavirin for 48 weeks in Chinese patients with chronic hepatitis C.

Authors:  S-H Zhao; Y-L Chu; D-X Cheng; A B Waqar; Q Yu; P-H Yang; X Xue; H-J Yang; E-Q Liu
Journal:  Int J Clin Pract       Date:  2009-09       Impact factor: 2.503

10.  Peginterferon-alpha2a and ribavirin combination therapy in chronic hepatitis C: a randomized study of treatment duration and ribavirin dose.

Authors:  Stephanos J Hadziyannis; Hoel Sette; Timothy R Morgan; Vijayan Balan; Moises Diago; Patrick Marcellin; Giuliano Ramadori; Henry Bodenheimer; David Bernstein; Mario Rizzetto; Stefan Zeuzem; Paul J Pockros; Amy Lin; Andrew M Ackrill
Journal:  Ann Intern Med       Date:  2004-03-02       Impact factor: 25.391

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.